Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NORVAX Compact PD
- Development stage
- Unknown
- Lead developer
- Intervet
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal
01
Overview
NORVAX Compact PD is an inactivated veterinary vaccine developed by MSD Animal Health for the active immunization of Atlantic salmon (*Salmo salar*). It is specifically formulated to reduce heart lesions, mortality, and weight loss associated with Pancreas Disease (PD) caused by Salmonid Alphavirus (SAV). The vaccine contains the inactivated Salmon pancreas disease virus (SPDV) strain F93-125 and is formulated as an emulsion for injection with the adjuvant Montanide ISA 763A VG. It is administered as a single 0.1 ml dose via intraperitoneal injection to provide protection against the clinical signs of PD in aquaculture settings.
- Brand names
- NORVAX Compact PD
Beyond the preview
Go deeper on NORVAX Compact PD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NORVAX Compact PD.